COA Available
GLP-1 In Stock Research Use Only
Survodutide
10mg · Lyophilized Powder · Purity ≥99%
Survodutide (BI 456906) is a synthetic dual agonist of the GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR), used as a pharmacological research tool in metabolic pathway research, hepatic lipid biology, and MASH-related preclinical investigations.
$159.99 CAD
Purchase Options
Subscriptions can be managed from your customer account. Prices in CAD.
Research Overview
Survodutide is a synthetic peptide that co-activates the GLP-1 receptor and the glucagon receptor (GCGR), enabling preclinical investigation of the combined pharmacological effects of incretin pathway activation — associated with insulin secretion modulation — alongside GCGR-mediated energy expenditure enhancement through cAMP/PKA signalling in hepatic and adipose tissue models. The compound has been studied in metabolic research contexts relevant to hepatic steatosis and metabolic-associated steatohepatitis (MASH) biology. BME Health supplies Survodutide as a lyophilized high-purity research peptide with Certificate of Analysis. Supplied exclusively for laboratory and research use.
Preclinical research has used Survodutide to examine the mechanistic biology of dual GLP-1R/GCGR co-activation in metabolic tissue models, with investigations exploring hepatic lipid handling, energy expenditure markers, and metabolic homeostasis parameters in animal and cell-based systems. The compound is in clinical development for MASH and obesity, with published clinical data informing its mechanistic research profile — however, it is not approved by Health Canada or the FDA. BME Health supplies Survodutide exclusively for preclinical laboratory research. All outcomes referenced do not constitute evidence of clinical efficacy or safety in humans.
Specifications
| Compound | Survodutide |
| Format | Lyophilized Powder |
| Size | 10mg |
| Purity (HPLC) | ≥99% |
| Item # | BME-SURVOD-A |
| Storage | −20°C, dry, dark |
| Price (CAD) | $159.99 |
COA / Testing
Batch documentation and third-party testing information are available for batch BME-SURVOD-A. COA previews appear only when documentation exists for the active batch.
Storage & Handling
Store lyophilized Survodutide at −20°C in a sealed, dry container protected from light. Avoid repeated freeze-thaw cycles after reconstitution; prepare working solutions in appropriate research-grade buffer vehicles as required for each experimental session. Vials should be examined for integrity upon receipt.
Shipping & Returns
Orders are processed on business days. Packaging is selected to maintain compound integrity in transit. Shipping timelines and return conditions are outlined in full in the Shipping & Returns policy — review before checkout if you have specific requirements. For orders with time-sensitive research schedules, contact support before placing your order.
Research Use Disclaimer
This product is supplied strictly for in-vitro and laboratory research use. It is not a drug, food supplement, or cosmetic and is not approved for human or veterinary clinical applications, diagnostics, or therapeutic use. Researchers are responsible for compliance with all applicable institutional and regulatory requirements in their jurisdiction.
Preparation Reference Guide
Research Solution Reference Calculator
Pre-filled with 10mg. Enter your solvent volume and target amount to see concentration and units on a U-100 syringe scale.
Concentration—
Volume to draw—
Syringe units (U-100)—
Per insulin unit—
For research-use calculations only. Always verify measurements independently — not medical guidance.
Questions before you order?
Browse the FAQ for documentation, storage, and sourcing answers, or contact our support team directly. We aim to respond to all research procurement inquiries within one business day.
